4D Pharma stock near 2-year highs after cancer drug trials

Having seen a far better than anticipated outcome from the opening trials of a cancer treatment, 4D Pharma CEO, Duncan Peyton, joins IGTV’s Jeremy Naylor. 4D is also in trials with a respiratory treatment that, it is hoped, can stem the worst effects of Covid-19 on the lungs. Peyton says that despite the higher numbers of people testing positive for this strain of coronavirus, the lack of numbers going into hospital, thankfully, means that there are far fewer candidates to sign up for drug testing.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews